SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance ...
First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing.
The tailor-made comprehensive offering spans a diversified clinical and commercial portfolio of innovative modalities, ...
Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...
Drug developers have a new, optimized option for U.S.-based manufacturing, as AGC Biologics enters a strategic partnership ...
OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics, a U.S.-based Contract Development and Manufacturing Organization (CDMO), announced the launch of its in-house formulation development services, ...
Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platform; Enables deployment of continuous manufacturi ...
HCW Biologics Inc. and WY Biotech Co., Ltd. have finalized a licensing agreement for the development and commercialization of HCW11-006, a novel immunotherapy targeting age-related diseases and cancer ...
SHANGHAI, June 24, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results